Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises AstraZeneca on Agreement With Cubist Pharmaceuticals


WASHINGTON, DC, July 11, 2008 — Cubist Pharmaceuticals, Inc. announced that it has signed an exclusive agreement with AstraZeneca to promote and provide support in the United States for MERREM® I.V. Covington & Burling LLP advised AstraZeneca on the deal.

AstraZeneca, a major international healthcare business, is engaged in the research, development, manufacturing and marketing of prescription medicines. Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

The Covington team included Washington-based partner John Hurvitz and San Francisco-based associate Amy Toro. The AstraZeneca legal team included Sara Ponessa and Richard Kenny.

Share this article: